Commentary: Keep medicine out of the US-China tech war

The article suggests that novel medicines differ from sectors like semiconductors or electric vehicles, where one competitor's gain often comes at another's expense. In medicine, collaboration is presented as a possibility even amidst the US-China technology competition, implying that the nature of the product itself can influence geopolitical dynamics.

China's ambition to lead in biotechnology, as outlined in its five-year plan, includes specific quantitative targets for drugmakers by 2030. These targets, such as developing a quarter of the world's first-in-class medicines and creating five blockbuster therapies, are viewed as potentially achievable, supported by past policy and educational investments.

Major pharmaceutical companies globally have reportedly increased their engagement with Chinese drug development. The value of overseas drug-licensing deals has surged over the past five years, reaching a record US$134 billion. This trend is driven by the need to replenish drug pipelines ahead of patent expirations, particularly in areas like cancer and obesity treatments where China is noted for its contributions.